CompletedNCT00499863
Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD
Researchers compared methylphenidate transdermal system and placebo to find out how the approaches affected ADHD symptoms in young people with ADHD.
Medication studyAges 13–17United States
Understand this study
What did researchers investigate?
Researchers compared methylphenidate transdermal system and placebo to find out how the approaches affected ADHD symptoms in young people with ADHD.
Who was this study for?
Listed age limits: 13 years to 17 years.
- Listed locations
- Scottsdale, United States · Lafayette, United States and 30 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateJuly 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 217
- Sponsor
- Noven Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 13 Years to 17 Years
- Official registry ID
- NCT00499863
- Official title
Show the full official title
A Phase IIIb, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Efficacy and Safety of MTS in Adolescents Aged 13-17 Years With ADHD
Recruitment & locations
CompletedScottsdale · Lafayette · Wildomar
29 more locations
- Gainesville
- South Miami
- Roswell
- Eagle
- Overland Park
- Lexington
- Paducah
- Rochester Hills
- Troy
- Clementon
- Durham
- Fargo
- Minot
- Cleveland
- Eugene
- Portland
- Media
- Philadelphia
- Providence
- Memphis
- Austin
- Bellaire
- Lubbock
- San Antonio
- Burlington
- Herndon
- Midlothian
- Friday Harbor
- Kirkland
Questions about this study
What did researchers investigate?
Researchers compared methylphenidate transdermal system and placebo to find out how the approaches affected ADHD symptoms in young people with ADHD.
Who is behind this study?
The study sponsor is Noven Therapeutics.
Did this study involve medication?
Yes. The study involved medication, including methylphenidate transdermal system and Placebo.
Who was this study for?
Listed age limits: 13 years to 17 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT02059642
MG01CI 1400 mg Compared With Placebo for ADHD
Researchers compared MG01CI (1400 mg) and placebo to find out how the approaches affected ADHD symptoms in adults with ADHD.
CompletedNCT00500149
Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) for ADHD
United States
CompletedNCT02555150
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
United States